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Summary.-The immunofluorescent reaction of peripheral blood cells from 10
multiple myeloma, 10 Hodgkin's and 11 lymphosarcoma cases with antiviral
(Rauscher) murine leukaemia (AMR) and antihuman stem cell leukaemia plasma
(AHS) antisera was studied. Cells from 25 of these patients were reactive at least
once with AMR and AHS or AHS alone. Absorption studies suggested that this
cytoplasmic immunofluorescent reaction involved cellular isoantigens. Serial
studies on multiple myeloma, Hodgkin's and lymphosarcoma cases with significant
fluorescence, showed that the fluorescent cell count variation was correlated with the
presence of active disease.
PREVIOUS studies (Fink et al., 1965;
Joannides, Rosner and Lee, 1968; Bates,
Bankole and Swaim, 1969) reported that
blood cells from patients with Hodgkin's
disease, multiple myeloma, and other
lymphomata fluoresced when reacted with
antimurine leukaemia virus (Rauscher) or
antihuman leukaemia plasma antiserum.
In another report (Swaim et al., 1971) the
onset of myelogenous leukaemia in a
patient with Hodgkin's disease was charac-
terized by the appearance of nucleated
peripheral blood cells which fluoresced
when reacted with the above described
leukaemia antiserum.
The following study was directed
towards determining: (1) the antigens
involved in fluorescence by peripheral
blood cells from Hodgkin's disease,
multiple myeloma and lymphosarcoma
patients, (2) whether this fluorescence was
variable or continuous over a period of
time, and (3) the relationship between
cellular fluorescence and patient's clinical
state.
MATERIALS AND METHODS
Preparation of antiserum
Preparation, conjugation and tissue ab-
sorption of leukaemia virus (Rauscher)
monkey antiserum (AMR)* and rabbit anti-
sera against human stem cell leukaemia
plasma pellet (AHS) were carried out as
described previously (Bates et al., 1969).
Leukocyte absorption and immunological
specificity
Leukocytes from 30 individuals with
normal blood cell morphology and counts
were pooled and triturated on a Ten Broeck
grinder. To this material was added an
equal volume of phosphate (0-10 mol/l)
buffered saline (0a15 mol/1) pH 7-2 (PBS).
To 2 ml of conjugated serum (AMR or AHS)
wasadded0-2 mlofthe cellular extract. This
mixture was reacted at 37°C for 2 hours with
occasional shaking and then centrifuged at
5000 g for 60 min.
The supernatant was removed and re-
acted, as described below with the leuko-
cytes studied. Immunological specificity was
determined by methods described previously
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(Bates, et al., 1969). Additional " immuno-
logical blocking" reactions were carried out
by reacting absorbed, unconjugated AMR
and AHS with nucleated blood cells of
multiple myeloma, Hodgkin's and lympho-
sarcoma cases.
Specimen sources
Peripheral blood specimens from patients
with multiple myeloma, Hodgkin's disease,
lymphosarcomata, carcinomata and infec-
tious mononucleosis were obtained from the
Minneapolis Veterans Hospital, Minneapolis,
Minnesota, and the Swedish Hospital of
Minneapolis, Minnesota. Specimens for nor-
mal controls were obtained from the obstet-
rics and gynaecological service of the latter
hospital.
Preparation, staining and interpretation of
reactions
Preparation and staining have been
described (Bates et al., 1969). Briefly,
centrifugation (1000 g) at 20°C was used to
separate the leukocytes from red cells and
plasma. The leukocyte layer was removed,
diluted 1: 10 in PBS and recentrifuged.
These sedimented leukocytes were then
spread on to the surface of a glass slide, air
dried 5 min and then fixed in cold (4'C)
acetone for 30 min. " Fixed " leukocytes were
stored at - 20°C until stained. When
stained, the specimen was reacted 30 to 45
min at 20°C under moist conditions with
tetramethylrhodamine gelatin (Bohlool and
Schmidt, 1968) mixed with an equal volume
Nor
Cars
of AMR or AHS. After staining, the speci-
men was washed in phosphate buffer pH 7-6,
0 01 mol/l, air dried and mounted just prior
to examination in buffered glycerol (9 parts
glycerol, 1 part phosphate buffer pH 7-8,
0-02 mol/l). A Leitz microscope with an u.v.
barrier filter was used to examine the smears.
Cells were observed with a 54 x oil
immersion objective lens. Depending on the
number of cells present, 100-1000 nucleated
cells were studied and the intensity of cyto-
plasmic fluorescence graded as non-reactive
(NR), weakly reactive (WR), reactive (R) or
strongly reactive (SR). For each specimen
4 slides were prepared and reacted with AMR
and AHS. Nuclear fluorescence was rarely
observed. If 5% or more of the total
observed nucleated cells in the 4 slides were
R to SR, immunofluorescence was considered
significant. The 5% value was determined
after observing that normal blood specimens
showed 0 to 2% oftheir cells R with absorbed
AMR and AHS. When specimens obtained
from a patient at different time intervals were
R to SR and the percentage of cells with
fluorescence in the respective specimens
varied more than + 14% (2 S.D.), this was
considered significant fluorescent variation.
The technical variation for this study was
determined on cells from a patient with
myelogenous leukaemia. Twenty-five blood
smears were prepared from one blood speci-
men and the number of cells/100 nucleated
cells showing significant cytoplasmic fluores-
cence determined. The range was 21 to 28
with a mean positive fluorescence cell count
of 24 + 7% (1 S.D.).
TABLE I.-Fluorescent Antibody Results Obtained on Peripheral Blood Cellsfrom
Multiple Myeloma, Hodgkin's Disease and Lymphosarcoma Cases
No. cases Sig. FAt
No. cases Sig. FA* Variation
No. , A_ _
Group cases AMRI AMR/AHS§ AHS None AMR AMR/AHS AHS None
mals . .60 0 0 0 60 . 0 0 0 0
3inoma . .30 0 0 0 30 * 0 0 0 0
Infectious
mononucleosis
Multiple myeloma .
Hodgkin's
Lymphosarcoma
9
10
10
11
0
0
0
0
0
2
3
4
0
7
4
5
9
1
3
2
0
0
0
0
0
2
3
4
0
5
2
0
0
3
5
2
* Significant fluorescence.
t Leukocytes obtained at different time intervals from cases and which varied 14 0 or more in the No. of
leukocytes with fluorescence.
t Reactive only with AMR.
§ Reactive with both AMR and AHS.
11 Reactive only with AHS.
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After 2 absorptions of AMR and AHS
with pooled W.B.C., nucleated peripheral
blood cells from the controls (Table I)
were NR to both AMR and AHS, and the
multiple myeloma and Hodgkin's lym-
phosarcoma cases were R to SR (Fig. 1).
When nucleated blood cells from the latter
cases were first reacted with absorbed
unconjugated AMR or AHS, and then
absorbed conjugated AMR or AHS, fluor-
escence was NR to WAR. Pretreatment
with normal rabbit or human plasma did
not " block " fluorescence by these cells.
Nine of 10 multiple myeloma, 7 of 10
Hodgkin's and 9 of 11 lymphosarcoma
cases listed in Table I had significant
fluorescence with both AMR and AHS or
AHS but never AMR alone.
Significant fluorescent cell count vari-
ations occurred in 7 of 10 multiple
myeloma, 5 of 10 Hodgkin's and 9 of 11
lymphosarcoma cases. All of these cases
were males under treatment, whose dis-
eases were diagnosed prior to this study.
The carcinoma cases listed in Table I
were randomly selected from a terminal
cancer home (STP) and under cancer
treatment.
DISCUSSION
Nucleated peripheral blood cells from
25 of 31 Hodgkin's disease, multiple
myeloma and lymphosarcoma cases show-
ed cytoplasmic fluorescence when reacted
with AMR and AHS or AHS alone. None
were reactive with AMR alone. Controls
were non-reactive. Immunological block-
ing and absorption studies indicated that
this fluorescence was not characteristic of
normal leukocytes.
Since not all normal leukocyte iso-
antigens are known, interpretation ofthese
data is difficult. One cytotoxicity study
(Peacocke et al., 1966) showed that
chronic lymphatic leukaemic cells con-
tained normal leukocyte isoantigens with
normal or above normal frequency. In
our study, repeated absorption of AMR
and AHS with normal leukocytes resulted
in the following progressive reduction in
cytoplasmic fluorescent activity (normals,
carcinomata, infectious mononucleosis,
Hodgkin's, lymphosarcoma, myelogenous
leukaemia).
Biophysical reactions associated with
absorption could account for some loss of
fluorescent activity. However, its pro-
gressive loss indicated that these cells
contained different concentrations of the
antigen(s) being detected. The signifi-
cance of this antigen(s) in respect to
aetiology ofthese diseases is not known.
As in human leukaemia (Fink et al.,
1965; Yohn et al., 1968) a viral aetiology
was considered. In our study, absorption
of AMR with normal human leukocytes
reduced its fluorescent activity. The
presence in human leukocytes of Rauscher
virus antigenic determinants wasdifficult
to comprehend.
One explanation was that the prepara-
tion of leukocytes for absorption, altered
or exposed " masked " leukocyte antigens
common to this virus.
This offered an explanation for absorp-
tion results but failed to explain why the
concentration of this antigen(s) increased
in active states of the described diseases.
WAe postulated that the presence ofthis
antigen(s) indicated a cellular disorder
with a common metabolic pathway.
Whether this pathway was viral, drug, or
radiation induced remains unanswered.
Serial studies on described cases
showed a variation in fluorescent intensity
and percentage of cells positive. This
variation was also observed in our leu-
kaemia study Bates et al., 1969).
In the latter study the presence of
fluorescing peripheral blood cells corre-
lated with haematological parameters
indicative of active leukaemia. Although
no correlation with haematological find-
ings was evident in the present study, a
relationship existed between active disease
and the presence offluorescing cells. The
aetiological significance of these findings
was discussed.
CASE REPORTS (TABLE II)
Case No. 150 (multiple myeloma) was
diagnosed in 1962. Cellular fluorescenceBRITISH JOURNAL OF CANCER
FIG. 1.-Fluorescent reactions of peripheral blood cells from described cases with absorbed AHS or
AMR: (a) normal, (b) acute lymphoblastic leukaemia, (c) lymphosarcoma (case No. 66C, Table II),
and (d) Hodgkin's disease (case No. 227, Table II). x 540.
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TABLE II.-Selected Serial Studies on Multiple Myeloma, Hodgkin's and
Lymphosarcoma Patients
Disease
Multiple myeloma
Case No.
150
Multiple myeloma 80
Multiple myeloma 103
Hodgkin's 227
Hodgkin's 222
Lymphosarcoma 66C
Lymphosarcoma 255
Date specimen
obtained
8/67
12/67
2/68
5/68
6/68
1/68
2/68
4/68
6/68
10/68
7/67
9/67
1/68
2/68
4/68
5/68
10/68
11/67
5/68
7/68
8/68
9/68
* 7/68
8/5/68
8/9/68
6/67
8/67
9/67
10/67
1/68
8/68
11/68
-
AMR
NR
WR
WR
NR
NR
NR
R
WR
NR
NR
NT§
NR
WR
NR
NR
WR
NR
NR
WR
NR
R-SR
R-SR
R-SR
NR
R-SR
NR
NR
WR
R-SR
R-SR
NR
NR
Fluorescent reactiont
%Pt AHS
0 NR
10 R-SR
10 R-SR
0 WR
0 WR
0 NR
25 R-SR
10 R-SR
0 WR
0 WR
- NR
10 WR
5 R-SR
0 WR
0 NR
20 R-SR
0 NR
0 NR
5 WR
0 NR
30 R-SR
30 R-SR
30 R-SR
0 NR
10 R-SR
0 NR
0 NR
10 WR
20 R-SR
20 R-SR
0 NR
0 NR
* Case summaries at end of discussion. Cases were selected from those reported in Table I.
t Fluorescent reaction: NR = non-reactive, WR = weakly reactive, R = reactive, and SR = strongly
reactive.
$ %P (positive) =
observed fluorescing cells x 100. total cells observed
(For convenience, % values are expressed in nearest multiples of 5.)
§ NT = not tested.
from December 1967 to February 1968 was
preceded by cytoxan-induced anaemia and
thrombocytopenia.
Case No. 80 (multiple myeloma) was diag-
nosed in November 1966. Cytoxan failed to
control the disease and the patient died in
January 1969.
Case No. 103 (multiple myeloma) was
diagnosed in November 1966. Cytoxan
therapy was utilized. The patient gradually
deteriorated and died in January 1969.
Periods of accelerated clinical deterioration
were correlated with positive cellular
fluorescence.
Case No. 227 (Hodgkin's disease) was
diagnosed in 1962 and was treated with
electron beam therapy from a linear accel-
erator. Chlorambucil was given in 1967 and
continued until September 1968, when the
patient relapsed. Therapy was changed to
cytoxan plus prednisone and then to vinca-
leukoblastine (VLB). At the time ofrelapse,
cellular fluorescence was positive.
In 1961, case No. 222 (Hodgkin's disease)
had a cervical lymphosarcoma treated with
radiation therapy. In July 1968 a left upper
quadrant mass was detected. A splenectomy
and biopsy of retroperitoneal nodes and liver
%P
0
30
40
30
10
0
35
15
20
5
0
25
10
20
0
25
0
0
10
0
40
30
30
0
20
0
0
10
20
30
0
0
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were done. Pathological examination showed
Hodgkin's disease in the retroperitoneal
nodes and spleen and lymphosarcoma in the
liver. Cellular fluorescence was positive.
The patient was treated with cytoxan and
cellular fluorescence became negative. When
discharged cellular fluorescence was again
positive.
Case 66C (lymphosarcoma) was diagnosed
in July 1962. The patient was treated with
radiation in 1966 and was asymptomatic until
he relapsed in January 1967. The disease
was controlled by Cytoxan until October
1967, when patient relapsed and cellular
fluorescence became positive.
Case No. 255 (lymphosarcoma) was
diagnosed in 1965. In November 1967 an
abdominal mass was detected and treated
with chlorambucil. By January 1968 it was
considered " residual " but cellular fluores-
cence was positive. In August and Novem-
ber 1968 this mass was not detectable and
cellular fluorescence was negative.
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